Daiichi Sankyo and The Kitasato Institute’s Research Organization for Infection Control Sciences will discover and develop vaccine seeds together and proactively obtain licenses and technologies from third parties to respond to unmet medical needs of the market by providing highly safe and effective vaccines.
Daiichi Sankyo has shown interest in The Kitasato Institute and its next generation recombinant vaccine technology that uses the internationally-respected AIK-C strain measles vaccine as a vector.